Indications and Usage

Elotuzumab is FDA approved for the treatment of multiple myeloma

• In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.
• In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. 

Side effects needing medical attention

Infusion reactions (such as fever, trouble breathing, chills, dizziness, rash, light-headedness); infections; risk of new cancers (malignancies); liver problems; fatigue; numbness, weakness, tingling, or burning pain in your arms or legs; diarrhea; sore throat or runny nose; fever; upper respiratory tract infection; constipation; decreased appetite; cough; pneumonia.

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.